<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>160-DAPTOMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DAPTOMYCIN" rxcui="22299">
<ATC code="J01XX09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Risk of addition of undesirable effects (dose dependent) of the rhabdomyolysis type.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, reinforce biological monitoring (CPK levels more than once a week) and strict clinical monitoring. </COMMENT>
</INTERACTION>
</INTERACTIONS>
